Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Cell Therapy + PTA vs PTA in Diabetic Chronic Limb-Threatening Ischemia
2024-512873-29-00Phase 2Authorised
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Feb 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous bone marrow-derived mononuclear cell in chronic limb-threatening ischemia (CLTI), diabetic foot ulcer (DFU), diabetes mellitus type 1 (T1D) and 1 more (2 arms), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoints: Rate of major amputation, Wound healing and 1 more. Planned start Feb 2025; status: authorised.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
chronic limb-threatening ischemia (CLTI)diabetic foot ulcer (DFU)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-512873-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512873-29-00.